Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.39 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25222090 | 1.00 | HTT (0.39) | HTTLMNAPGRCYP3A4CYP2D6 | |
| SCHEMBL3390275 | 1.00 | HTT (0.39) | HTTLMNAPGRCYP3A4CYP2D6 | |
| SCHEMBL3388087 | 1.00 | HTT (0.39) | HTTLMNAPGRCYP3A4CYP2D6 | |
| SCHEMBL3387155 | 1.00 | HTT (0.39) | HTTLMNAPGRCYP3A4CYP2D6 | |
| SCHEMBL3389358 | 1.00 | HTT (0.39) | HTTLMNAPGRCYP3A4CYP2D6 | |
| SCHEMBL6567295 | 0.77 | LMNA (0.33) | HTTLMNAPGRCYP3A4CYP2D6 | |
| SCHEMBL29001831 | 0.71 | LMNA (0.36) | HTTLMNAPGRCYP3A4CYP2D6 | |
| SCHEMBL1987501 | 0.71 | CYP4F2 (0.31) | HTTLMNAPGRCYP3A4CYP2D6 | |
| SCHEMBL4199013 | 0.69 | GAA (0.41) | LMNAMAPTMAPK1TDP1 | |
| SCHEMBL3398907 | 0.68 | TRPA1 (0.40) | HTTLMNAPGRCYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1839653-B9 | THERAPEUTIC AGENT FOR SENSORY DISORDERS | MEIJI DAIRIES CORP (JP) | 2010-12-22 | — | — | EP | claimed |
| EP-2196200-A1 | Cyclohexenone derivative for treating or preventing hypesthesia or hyperesthesia caused by diabetes | Meiji Dairies Corporation (JP) | 2010-06-16 | — | — | EP | claimed |
| EP-1839653-B1 | THERAPEUTIC AGENT FOR SENSORY DISORDERS | MEIJI DAIRIES CORP (JP) | 2010-06-09 | — | — | EP | claimed |
| US-20090069442-A1 | Therapeutic Agent for Sensory Abnormality | MEIJI CO., LTD (JP) | 2009-03-12 | — | — | US | claimed |
| US-20080312336-A1 | Preventive and/or Therapeutic Agent for Diabetic Vascular Disorder and Respiratory Disorder | UNIVERSITE DE STRASBOURG (FR) | 2008-12-18 | — | — | US | claimed |
| EP-1839653-A1 | THERAPEUTIC AGENT FOR SENSORY ABNORMALITY | Meiji Dairies Corporation (JP) | 2007-10-03 | — | — | EP | claimed |
| EP-1003706-B1 | CYCLOHEXENONE LONG-CHAIN ALCOHOL AND MEDICAMENT CONTAINING SAME | MEIJI MILK PROD CO LTD (JP) | 2003-03-05 | — | — | EP | claimed |
| US-6228893-B1 | TREATING DEMENTIA | MEIJI MILK PRODUCTS CO., LTD. (JP) | 2001-05-08 | — | — | US | claimed |
| EP-1839653-B9 | THERAPEUTIC AGENT FOR SENSORY DISORDERS | MEIJI DAIRIES CORP (JP) | 2010-12-22 | — | — | EP | disclosed |
| EP-2196200-A1 | Cyclohexenone derivative for treating or preventing hypesthesia or hyperesthesia caused by diabetes | Meiji Dairies Corporation (JP) | 2010-06-16 | — | — | EP | disclosed |
| EP-1839653-B1 | THERAPEUTIC AGENT FOR SENSORY DISORDERS | MEIJI DAIRIES CORP (JP) | 2010-06-09 | — | — | EP | disclosed |
| US-20090069442-A1 | Therapeutic Agent for Sensory Abnormality | MEIJI CO., LTD (JP) | 2009-03-12 | — | — | US | disclosed |
| US-20080312336-A1 | Preventive and/or Therapeutic Agent for Diabetic Vascular Disorder and Respiratory Disorder | UNIVERSITE DE STRASBOURG (FR) | 2008-12-18 | — | — | US | disclosed |
| EP-1839653-A1 | THERAPEUTIC AGENT FOR SENSORY ABNORMALITY | Meiji Dairies Corporation (JP) | 2007-10-03 | — | — | EP | disclosed |
| US-7166642-B1 | Use of cyclohexenone long-chain alcohol for treating neurodegenerative diseases | MEIJI DAIRIES CORPORATION (JP) | 2007-01-23 | — | — | US | disclosed |
| EP-1150667-B1 | CYCLOHEXENONE LONG-CHAIN ALCOHOL FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | MEIJI DAIRIES CORP (JP) | 2004-07-14 | — | — | EP | disclosed |
| EP-1150667-A1 | CYCLOHEXENONE LONG-CHAIN ALCOHOL FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | Meiji Dairies Corporation (JP) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000047199-A1 | USE OF A CYCLOHEXENONE LONG-CHAIN ALCOHOL FOR TREATING NEURODEGENERATIVE DISEASES | MEIJI DAIRIES CORPORATION (JP) | 2000-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312336-A1 | Preventive and/or Therapeutic Agent for Diabetic Vascular Disorder and Respiratory Disorder | CPT1B, CHRM1, ADRA1D | HTT 4586/4885LMNA 785/4885PGR 4528/4885 |
| US-20090069442-A1 | Therapeutic Agent for Sensory Abnormality | PMP22, NGF, HRH1 | HTT 2143/4885LMNA 3556/4885PGR 4625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.